Taro Pharma, the subsidiary of pharmaceutical major Sun Pharma on October 27, reported a net profit of $8.5 million for the July-September quarter. The company had posted a net loss of $2.8 million in the year-ago period.
The company's bottomline was also slightly dragged down by one-time exceptional charges, excluding which, the net profit came at $14.3 million.
Taro Pharma also clocked in an operating income of $4.7 million as against a loss of $6.8 million in the base period. Excluding the impact of the one-time exceptional item, the operating income stood at $10.9 million.
Also Read: Sun Pharma subsidiary recalls anti-depression drugs in US market
Revenue for the company came at $148 million, up 13.4 percent from $130.5 million recorded in the same quarter of the previous fiscal.
The firm attributed the rise in revenue to a one-time gross to net adjustment. Excluding that, the company's sales growth was in mid-single digits.
Nonetheless, positive earnings from Taro Pharma is also expected to boost parent Sun Pharma's consolidated earnings after being a drag in the recent quarters. Sun Pharma is slated to release its quarterly earnings on November 1.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
